After a median follow-up of 2.8 years, the 3-year relapse-free survival rate in patients with <em>BRAF</em>-mutant stage III melanoma who were treated with adjuvant dabrafenib and trametinib was 58% compared with 39% for placebo, according to findings from the phase III COMBI-AD study.
Axel Hauschild, MD
After a median follow-up of 2.8 years, the 3-year relapse-free survival (RFS) rate in patients withBRAF-mutant stage III melanoma who were treated with adjuvant dabrafenib and trametinib was 58% compared with 39% for placebo (HR, 0.47; 95% CI, 0.39-0.58;P<.001), according to findings from the phase III COMBI-AD study presented at the 2017 ESMO Congress and simultaneously published in theNew England Journal of Medicine.1,2
Early data for overall survival (OS) showed that 86% of patients in the combination arm were alive at 3 years versus 77% with placebo (HR, 0.57; 95% CI, 0.42-0.79;P= .0006). At the interim analysis, the OS advantage was not yet deemed statistically significant, according to predefined criteria that required aPvalue of .000019.
“This is a very remarkable hazard ratio and if you look at thePvalue for the primary endpoint of RFS there are 13 zeroes, and therefore it is very impressive,” said lead investigator Axel Hauschild, MD, Professor of Dermatology, University of Kiel, Kiel, Germany. “For overall survival, there was a 43% reduction in the risk of dying from metastatic melanoma. A very impressive result that is maintained over time.”
The study randomized 870 patients withBRAFV600E/K stage III melanoma to receive dabrafenib plus trametinib (n = 438) or placebo (n = 432). All patients were within 12 weeks of complete surgical resection and had stage IIIa (18%), IIIb (41%), and IIIc (40%) disease. Dabrafenib was given at 150 mg twice daily with trametinib at 2 mg once daily for 12 months. The salvage therapies received following the study were similar in each arm, and, in some cases, included a rechallenge with BRAF/MEK inhibition, Hauschild noted.
"Both the placebo and the combination group received the same amounts of salvage therapy. Seventy-four percent of the patients received systemic treatment for progressive disease," he said. "It is unlikely that overall survival was impacted by the salvage therapies, since it was so balanced between the two groups."
The median RFS was not reached with the combination versus 16.6 months for placebo. RFS was improved with dabrafenib/trametinib across all subgroups, Hauschild noted. "There was not a single outlier,” he noted. “All 3 stages benefited from the combination in the same way.” Hazard ratios across all subgroups ranged from 0.33 to 0.55 in favor of dabrafenib and trametinib versus placebo.
The 1-year OS rates were 97% versus 94% and the 2-year OS rates were 91% and 77% for the combination and placebo groups, respectively. The 1-year RFS rates were 67% versus 56% and the 2-year rates were 67% versus 44% for dabrafenib and trametinib versus placebo, respectively. The most common locations of recurrence, for the combination and placebo, respectively, were locoregional (12% vs 25%), distant (22% vs 29%), and both local and distant (2% vs 2%).
The risk of distant metastases or death was reduced by 49% with the combination versus placebo (HR, 0.51; 95% CI, 0.40-0.65). Additionally, there was a 53% improvement in freedom from recurrence with the combination (HR, 0.47; 95% CI, 0.39-0.57).
Adverse events (AEs) were experienced by 97% of those treated with dabrafenib and trametinib versus 88% with placebo. The rates of grade 3/4 AES were 41% and 14% for the combination and placebo, respectively. Overall, AEs led to discontinuation for 26% of those in the combination arm versus 3% with placebo. The most common all-grade AEs, which were mostly grade 1/2, with the combination were pyrexia (63%), fatigue (47%), and nausea (40%).
"There were fortunately no fatal adverse events with the combination of dabrafenib and trametinib. There were no new toxicities that were not described for stage IV melanoma," said Hauschild. "There were AEs leading to discontinuation in 26% of the patients, which is a bit more than we expected in advance but this is the adjuvant setting so the pressure on the patient to continue getting therapy is lower than in the stage IV setting.
The FDA initially granted an accelerated approval to the combination of dabrafenib and trametinib for patients withBRAF-mutant metastatic melanoma in January 2014. The combination received a full approval in November 2015, and is now also indicated for the treatment of patients withBRAF-mutant nonsmall cell lung cancer.
The baseline characteristics were similar between groups. In the combination arm, the median age of patients was 50 years and 91% of tumors had theBRAFV600E mutation with the remainder having the V600K alteration. Most patients (92%) had an ECOG performance status of 0. Twelve percent of patients in the combination group had in-transit metastases versus 8% with the placebo. Seventeen percent of patients had ≥4 positive lymph nodes, with the remainder having <4.